Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
 Printer Friendly  Send to a Friend

Genetic Cause of Statin-Related Muscle Pain Found

British researchers identify variant that increases risk of myopathy at high doses

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Alzheimer's Disease
Aneurysms
Angina Pectoris
Angiogram
More...

Related Healthscout Videos
 border=
Importance of Good Nutrition
Controlling Incontinence
Preventing Heart Disease the Easy Way
Lifestyle Changes for Heart Disease Prevention and Treatment
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Coronary Bypass Surgery
Erectile Dysfunction
More...

Related Drug Information
 border=
Accupril
Actonel
Altace
Avapro
More...

Related News Articles
 border=
Little-Known Fat Can Be a Heartbreaker
Is Human Growth Hormone a Key to Longevity?
Antibiotics May Not Cause Diarrheal Bacteria
Racial Disparities Exist in Head and Neck Cancer Outcomes
More...

WEDNESDAY, July 23 (HealthDay News) -- British researchers have discovered a genetic variant that causes some people who take cholesterol-lowering statins to have the muscle weakness called myopathy.

"We found a variant that affects the transport of statins into the liver," said Dr. Rory Collins, a professor of medicine and epidemiology at the University of Oxford and a leader of the group reporting the discovery in the July 24 online issue of the New England Journal of Medicine. "That variant produces a high level of blood statins and accounts for the greatest proportion of myopathy in people who use statins."

Text Continues Below



That side effect is not common, although it has been reported in a number of studies. It occurs in fewer than one of every 1,000 people taking statins. The new study indicates that one copy of the myopathy-related variant is carried by about a quarter of the population, Collins said, with a much smaller percentage carrying two copies. The variant accounts for about 60 percent of all statin-related myopathy cases, Collins said.

"It causes a substantial increase in relative risk," he said. "The risk is increased about fourfold for those who have one variant version of the gene, about 15-fold for someone who inherits two variant versions."

All human genes come in pairs, one from each parent.

Even when the variant version is present, the risk of myopathy depends on how big a dose of a statin is prescribed, Collins said. "For the statin doses most usually used, 20 to 40 milligrams of simvastatin, for example, the risk of myopathy is very low," he said. "Using a high dose for someone at high risk, the absolute risk of myopathy is maybe one in 1,000. With a standard dose, the risk would be about one in 10,000."

The myopathy caused by statins generally is not severe, and it disappears a day after the medication is stopped.

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 7/23/2008

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





SOURCES: Rory Collins, M.D., professor, medicine and epidemiology, Oxford University, England; Sekar Kathiresan, M.D., director, preventive cardiology, Massachusetts General Hospital, Boston; July 24, 2008, New England Journal of Medicine, online


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.